within Pharmacolibrary.Drugs.ATC.A;

model A10BD20
  extends Pharmacokinetic.Models.PK_1C_enteral(
    weight         = 70,
    F              = 0.5,
    Cl             = 25 / 1000 / 60,
    adminDuration  = 600,
    adminMass      = 1000 / 1000000,
    adminCount     = 1,
    Vd             = 0.08,
    Cmin           = 0.001,
    Cmax           = 0.01,
    Ctox_peak      = 0.02,
    Ctox_trough    = 0.01,
    ka             = 0.0011666666666666668,
    Tlag           = 600
  );

  annotation(Documentation(
    info ="<html><body><p>A fixed-dose combination of metformin (a biguanide that decreases hepatic glucose production and improves insulin sensitivity) and empagliflozin (a sodium-glucose co-transporter 2, SGLT2 inhibitor that reduces glucose reabsorption in the kidney). Used for the treatment of type 2 diabetes mellitus to improve glycemic control in adults; both substances are approved and widely used in combination therapy.</p><h4>Pharmacokinetics</h4><p>Estimated pharmacokinetic parameters for healthy adult subjects after oral administration, as no published population PK studies were found for the fixed-dose combination product. Parameters are approximate and based on known PK of separate metformin and empagliflozin oral administration.</p><h4>References</h4><ol><li><p>Lee, H, et al., &amp; Lee, S (2023). Pharmacokinetic Comparison Between a Fixed-Dose Combination of Empagliflozin L-Proline/Metformin and Empagliflozin/Metformin in Healthy Korean Subjects. <i>Clinical pharmacology in drug development</i> 12(12) 1156–1163. DOI:<a href=&quot;https://doi.org/10.1002/cpdd.1310&quot;>10.1002/cpdd.1310</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/37489552/&quot;>https://pubmed.ncbi.nlm.nih.gov/37489552</a></p></li><li><p>Donnan, K, &amp; Segar, L (2019). SGLT2 inhibitors and metformin: Dual antihyperglycemic therapy and the risk of metabolic acidosis in type 2 diabetes. <i>European journal of pharmacology</i> 846 23–29. DOI:<a href=&quot;https://doi.org/10.1016/j.ejphar.2019.01.002&quot;>10.1016/j.ejphar.2019.01.002</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/30639796/&quot;>https://pubmed.ncbi.nlm.nih.gov/30639796</a></p></li><li><p>Scheen, AJ, &amp; Paquot, N (2014). Metabolic effects of SGLT-2 inhibitors beyond increased glucosuria: A review of the clinical evidence. <i>Diabetes &amp; metabolism</i> 40(6 Suppl 1) S4–S11. DOI:<a href=&quot;https://doi.org/10.1016/S1262-3636(14)72689-8&quot;>10.1016/S1262-3636(14)72689-8</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/25554070/&quot;>https://pubmed.ncbi.nlm.nih.gov/25554070</a></p></li></ol></body></html>",
    revisions = "<html><body><ul><li>06/2025 model generated by LLM gpt-4.1, references by scholarly and scripts created by Tomas Kulhanek</li></ul></body></html>"
  ));
end A10BD20;
